October 2015

28 October 2015
October 28th, 2015, Grenoble, France- CYTOO announces today that Daiichi Sankyo Company Limited, a Japanese pharmaceutical manufacturer with global presence, has selected CYTOO in vitro muscle platform MyoScreen™ to develop a novel cell-based assay and screen drug candidates on a key mechanism involved in several muscular diseases.  MyoScreen™ is a high throughput and high content screening platform that enables the identification and characterization of new compounds that affect muscle hypertrophy, contractility, metabolism and muscular diseases. The system thus meets the broad...